FDA approves Opdivo for esophageal, gastroesophageal junction cancers

FDA approves Opdivo for esophageal, gastroesophageal junction cancers

The FDA approved nivolumab as adjuvant treatment for certain patients with completely resected esophageal or gastroesophageal junction cancers, according to the agent’s manufacturer.The approval applies to use of the agent by patients who have residual pathologic disease after neoadjuvant chemoradiotherapy and complete resection.Nivolumab (Opdivo, Bristol Myers Squibb), a PD-1 inhibitor, is the first immunotherapy approved for this patient population.The FDA based the approval on results of the randomized phase 3 CheckMate-577 trial, which included 794 patients with esophageal orRead More

Share on facebook
Share on twitter
Share on linkedin